Please login to the form below

Not currently logged in
Email:
Password:

disease progression

This page shows the latest disease progression news and features for those working in and with pharma, biotech and healthcare.

First-line ovarian approval cements AZ’s Lynparza lead

First-line ovarian approval cements AZ’s Lynparza lead

tube or primary peritoneal cancer, in order to reduce the risk of relapse or disease progression. ... progression-free at three years compared to 27% of a placebo group, with preliminary data a four years putting those proportions at more than 50% and 11%

Latest news

  • NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

    The draft highly specialised technologies guidance on Tegsedi (inotersen) and Onpattro (patisiran) concluded that both treatments slows progression of the disease and improve quality of life, but says uncertainty around these ... would help transform the

  • FDA fast tracks Novartis’ SMA gene therapy FDA fast tracks Novartis’ SMA gene therapy

    AveXis' David Lennon. AveXis, a neurological genetic disease focused company that Novartis acquired for $8.7bn in April this year, developed the therapy. ... Babies affected by this rare disease are currently faced with debilitating disease progression

  • ASH18: CAR-T and drugs give new options for multiple myeloma ASH18: CAR-T and drugs give new options for multiple myeloma

    as a maintenance therapy for the disease, after cutting the risk of disease progression or death by 28% compared to placebo in adult patients who’ve already been treated with ... the risk of disease progression or death by 57% compared to chemo alone

  • FDA green lights BMS’ multiple myeloma combo FDA green lights BMS’ multiple myeloma combo

    The results showed the combination could cut the risk of myeloma progression by 46% compared to Pomalyst and dexamethasone alone (Pd) This also demonstrated that the combination achieved an overall response ... BMS' Joseph Eid. “Empliciti plus

  • FDA clears first-line use for J&J’s myeloma drug Darzalex FDA clears first-line use for J&J’s myeloma drug Darzalex

    the risk of disease progression or death by 50% in these patients. ... J&J is also carrying out mid-stage testing of Darzalex even further up the treatment chain in ‘smouldering’ multiple myeloma, which is a precursor to full-blown disease that can

More from news
Approximately 1 fully matching, plus 213 partially matching documents found.

Latest Intelligence

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    stop or reverse disease progression. ... Explain to study subjects and caregivers they can’t expect improvements of PD symptoms, although they may benefit from a slower disease progression over time.

  • No incentive for a cure No incentive for a cure

    to 12-week course. And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to. ... Curative therapies have the potential to offset

  • A quest for innovative solutions A quest for innovative solutions

    disease progression. ... It is important that patients can see the value in tracking their disease.

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinson’s house'

    But this elegant home, surrounded by manicured lawns, is wired to beat the scourge of Parkinson’s disease. ... To show the stopping of disease progression can take a couple of years and that is a long time to conduct a clinical trial, so we hope we can

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    Improving patient adherence… is one way of improving this efficiency as there is decreased spending on hospitalisations, re-admissions, disease progression and complications.”. ... 80% in just five disease areas - asthma, type 2 diabetes, coronary

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

  • PatientsLikeMe names Jason Johnson as head of R&D PatientsLikeMe names Jason Johnson as head of R&D

    Johnson will lead the company's research, data science and informatics teams, which focus on analysing and merging patient-reported data and other data types to develop models of disease progression ... and generate new insights about disease, treatments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Artificial Intelligence in Healthcare

    Building upon and fusing technologies which exist today, AI promises to change everything, from the security of our online presence through to the way we diagnose and treat disease.[2]. ... It is thought that by anticipating the course of disease

  • How can pharma engage with Accountable Care Systems?

    There will be a big emphasis on disease prevention and delivering optimal patient journeys. ... In order to engage with ACSs, pharma needs to define how its products can help to prevent diseases and disease progression, and how they can add value across

  • Changing behaviour by design

    Loss aversion may also be applied to physician decision-making, while determining medication risk in relation to gains in quality of life, survival or disease-free progression etc, and when conveying

  • Living with Crohn's disease: a patient perspective

    What is it like to live with a  chronic disease  in your 20s? ... Despite progression in our knowledge of this condition, there is still a relatively poor understanding of this complex disease area, which inherently makes diagnosis even more difficult.

  • Ben Hwang discusses innovative diagnostic real-time monitoring data-sensors

    we monitor patients’ disease progression and treatment efficacy. ... Profusa have recently received approval for their first product to measure blood stats in respiratory disease.

More from PMHub
Approximately 0 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics